Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus;Efeito do tratamento com sitagliptina sobre os potenciais evocados somatossensoriais e controle metabólico de pacientes com diabetes melito tipo 2

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 4, 2014, Pages 369-376

  Barros, Joelma Ines Tagliapietra ^a   Fechine, Francisco Vagnaldo ^a   Montenegro Júnior, Renan Magalhães ^a   do Vale, Otoni Cardoso ^a   Fernandes, Virgínia Oliveira ^a   de Souza, Marcellus Henrique Loiola Ponte ^a   da Cunha, Gilmara Holanda ^a   de Moraes, Manoel Odorico ^a   d'Alva, Catarina Brasil ^a   de Moraes, Maria Elisabete Amaral ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Diabetes complications; Diabetes mellitus; Dipeptidyl peptidase IV inhibitors; Incretins; Type 2

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PYRAZINE DERIVATIVE; SITAGLIPTIN; TRIACYLGLYCEROL; TRIAZOLE DERIVATIVE;

ADULT; ANALYSIS; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; ELEMENTAL DIET; EVOKED SOMATOSENSORY RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC ACTIVATION; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ACTIVATION, METABOLIC; ADULT; ALANINE TRANSAMINASE; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; EVOKED POTENTIALS, SOMATOSENSORY; FASTING; FEMALE; FOOD, FORMULATED; GAMMA-GLUTAMYLTRANSFERASE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; STATISTICS, NONPARAMETRIC; TRIAZOLES; TRIGLYCERIDES;

EID: 84902581478     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000002914     Document Type: Article

References (25)

1. Guidoni CM, Borges APS, Freitas O, Pereira LRL. Prescription patterns for diabetes mellitus and therapeutics implications: a population-based analysis. Arq Bras Endocrinol Metab. 2012;56(2):120-27
2. Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res. 2003;37(5):471-80
3. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care. 2010;33(Suppl 1):S11-61
4. Legatt AD, Soliman E. Somatosensory evoked potentials: general principles. St. Petersburg: eMedicine Corporation; 2006
5. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300(3):958-66
6. Perry T, Haughey NJ, Matson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002;302(3):881-8
7. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007;203(2):293-301
8. Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induces diabetic rats. Arch Med Res. 2009;40(7):536-44
9. Sakamoto Y, Oyama J, Ikeda H, Kuroki S, Gondoh S, Iwamoto T, et al. Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol. 2013;12(1):35
10. Chiappa KH. Evoked potentials in clinical medicine. New York: Lippincott Williams & Wilkins; 1997
11. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell; 1994
12. Motulsky H. Intuitive biostatistics. Oxford: Oxford University Press; 1995
13. Visboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-13
14. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Met. 2006;91(11):4612-9
15. Kucera P, Goldenberg Z, Varsik P, Buranova D, Traubner P. Spinal cord lesions in diabetes mellitus. Somatosensory and motor evoked potentials and spinal conduction time in diabetes mellitus. Neuro Endocrinol Lett. 2005;26(2):143-7
16. Napoleão RM. Evoked potentials somatosensory median nerve in diabetic patients: correlations with biochemical markers. Dissertation (a Master degree in Medical Clinic), Faculty of Medicine, Federal University of Ceará, Ceará, Brazil, 2006
17. Misulis KE. Potencial evocado de Spehlmann. Rio de Janeiro: Revinter; 2003
18. Kikkawa Y, Kuwabara S, Misawa S, Tamura N, Kitano Y, Ogawara K, et al. The acute effects of glycemic control on nerve conduction in human diabetics. Clin Neurophysiol. 2005;116(2):270-4
19. Pozzessere G, Rizzo PA, Valle E, Mollica MA, Meccia A, Morano S, et al. Early detection of neurological involvement in IDDM and NIDDM. Multimodal evoked potentials versus metabolic control. Diabetes Care. 1998;11(6):473-80
20. Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288(5):G943-9
21. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634-40
22. Jolivalt CG, Fineman M, Deacon CF, Carr RD, Calcutt NA. GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab. 2011;13(11):990-1000
23. Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes. 2011;60(9):2397-406
24. Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol. 2011;164(5):1410-20
25. Bianchi R, Cervellini I, Porretta-Serapiglia C, Oggioni N, Burkey B, Ghezzi P, et al. J Pharmacol Exp Ther. 2011;340(1):64-72.